San Román José Alberto, Fernández-Avilés Francisco
Imaging Unit, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
Nat Clin Pract Cardiovasc Med. 2006 Mar;3 Suppl 1:S38-41. doi: 10.1038/ncpcardio0448.
Stem cell therapy after acute myocardial infarction is a promising therapeutic strategy. Intermediate-sized clinical trials to answer many unanswered questions must be carefully designed and surrogate end points carefully chosen. Moreover, imaging techniques accurate enough to measure surrogate parameters and to make it possible to reduce sample size are needed. The imaging technique of choice in this setting should be capable of tracking the destiny of the stem cells once injected in the heart and of quantifying left ventricular remodelling parameters. This information will be crucial in the design of multicenter, large, randomized trials to assess survival, which can definitively establish the usefulness of this therapeutic strategy.
急性心肌梗死后的干细胞治疗是一种很有前景的治疗策略。必须精心设计中级规模的临床试验以回答诸多未解决的问题，并谨慎选择替代终点。此外，还需要足够精确的成像技术来测量替代参数并有可能减少样本量。在这种情况下，首选的成像技术应能够追踪注入心脏后的干细胞命运，并量化左心室重构参数。这些信息对于设计评估生存率的多中心、大型随机试验至关重要，而此类试验能够最终确定这种治疗策略的有效性。
